85 search results for: type 2 inflammation

European Academy of Dermatology and Venereology (EADV) <b>2</b>0<b>2</b>3 | Berlin
Congress
11
October
2023
Congress
European Academy of Dermatology and Venereology (EADV) 2023 | Berlin

ADVENT Symposia brought global experts together to explore the latest advances in pediatric atopic dermatitis (AD), the shared and unique drivers of AD, prurigo nodularis (PN), and chronic spontaneous urticaria (CSU), and the pathology and patient management of PN.

ADVENT at EADV 2024
Congress
25
September
2024
Congress
ADVENT at EADV 2024

Join ADVENT at EADV 2024 congress (European Academy of Dermatology and Venereology) for 2 educational symposia on type 2 inflammation in atopic dermatitis and bullous pemphigoid. Visit Booth #A13 to learn more about type 2 inflammatory skin diseases with ADVENT.

 

ADVENT Forum 2025 Event Page
Awareness Day
4
April
2025
Awareness Day
ADVENT Forum 2025 Event Page

From the April 2025 ADVENT Forum in Lisbon, Portugal, this event page serves to spotlight curated soundbites from dermatology and immunology experts that connect the evolving science of type 2 inflammation to clinical application.

Skin Barrier Dysfunction in AD
Dermatology
Skin Barrier Dysfunction in AD
expert video

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel discusses how type 2 inflammation contributes to epidermal barrier dysfunction and AD signs and symptoms.

View more
Dysbiosis, Skin Infections, and Itch
Dermatology
Dysbiosis, Skin Infections, and Itch
expert video

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel presents how type 2 inflammation contributes to dysbiosis, skin infections, and itch in patients with AD.

View more
The Benefits of Early Intervention in Reducing the Burden of Disease in Children With Atopic Dermatitis
On Demand
The Benefits of Early Intervention in Reducing the Burden of Disease in Children With Atopic Dermatitis

This page presents educational material, infographics, and video highlights from our recent ADVENT symposia, including the 2025 World Congress of Pediatric Dermatology (WCPD) in Buenos Aires, Argentina, exploring the pathophysiology of type 2 inflammation and atopic dermatitis, the burden of disease leading to cumulative life course impairment (CLCI), and the risk of the atopic march in pediatric patients with atopic dermatitis.

European Academy of Allergy and Clinical Immunology (EAACI) <b>2</b>0<b>2</b>3 | Hamburg
Congress
9
June
2023
Congress
European Academy of Allergy and Clinical Immunology (EAACI) 2023 | Hamburg

Presentation highlights from the ADVENT symposium at the EAACI 2023 congress in Hamburg, Germany.

European Society for Pediatric Dermatology (ESPD) <b>2</b>0<b>2</b>4 | Košice, Slovakia
Congress
3
May
2024
Congress
European Society for Pediatric Dermatology (ESPD) 2024 | Košice, Slovakia

Inflammatory processes drive AD both within and beyond the skin, leading to significant, cumulative life impacts. Early intervention has the potential to mitigate these impacts by altering the disease course.

Cumulative Impact of Uncontrolled Atopic Dermatitis: Skin <b>Inflammation</b> as the Tip of the Iceberg
Dermatology
Cumulative Impact of Uncontrolled Atopic Dermatitis: Skin Inflammation as the Tip of the Iceberg
expert video

Prof Jean-David Bouaziz describes the multifaceted burden of atopic dermatitis, beyond what can be seen on the skin, at EADV 2025.

View more
World Congress of Dermatology (WCD) <b>2</b>0<b>2</b>3 | Singapore
Congress
4
July
2023
Congress
World Congress of Dermatology (WCD) 2023 | Singapore

Highlights from the ADVENT symposium at the 2023 World Congress of Dermatology in Singapore.

Charting the Future: Preventing the Atopic March
Dermatology
Charting the Future: Preventing the Atopic March
expert video

In this video from the April 2025 WCPD symposium, Dr Eulàlia Baselga discusses how early intervention during infancy and childhood in patients with AD may reduce the progression of the atopic march. Dr Baselga goes on to review data showing how the reduction of biomarkers such as IgE and CCL17 may reduce inflammation and sensitization that contribute to atopic comorbidities.

View more